SUCLG2 and posterior cortical atrophy: From the viewpoint of precisely tailoring PCa treatment to the needs of individual patients, our study ventured into the realm of pharmacogenomics to identify potential drugs that could serve as targeted therapies based on SUCLG2 expression levels.